Concepedia

Caitlyn Stromko

CS

Statistics

Publications

6

Citations

585

H-Index

6

Active since

2021

Affiliations

Bristol-Myers Squibb (United States)(Current)

Instituto do Câncer do Estado de São Paulo

Medical University of Vienna

Clinica Universidad de Navarra

Université Grenoble Alpes

Caitlyn Stromko is an author at Bristol-Myers Squibb (United States) specializing in cancer immunotherapy, medicine, and oncology.

Publications per year

2021–2025

6

Publications

6

Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial

Thomas Yau, Peter R. Galle, Thomas Decaens et al. · The Lancet · 2025 · 270 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW.

Peter R. Galle, Thomas Decaens, Masatoshi Kudo et al. · Journal of Clinical Oncology · 2024 · 146 citations

Medicine, Oncology, Pharmacology +15

Enhanced antitumor immunity by a novel small molecule HPK1 inhibitor

Dan You, Stephen Hillerman, Gregory Locke et al. · Journal for ImmunoTherapy of Cancer · 2021 · 76 citations · Full text

Medicine, Immunology, Pharmacology +17

Discovery of Orally Active Isofuranones as Potent, Selective Inhibitors of Hematopoetic Progenitor Kinase 1

Andrew P. Degnan, Godwin Kumi, Christopher W. Allard et al. · ACS Medicinal Chemistry Letters · 2021 · 54 citations · Full text

Medicine, Medicinal Chemistry, Oncology +17

DGKα/ζ inhibitors combine with PD-1 checkpoint therapy to promote T cell–mediated antitumor immunity

Michael Wichroski, Joseph L. Benci, Si-Qi Liu et al. · Science Translational Medicine · 2023 · 29 citations

Life Sciences, Immunology, Medicinal Chemistry +17

1–5 of 6